3,702 research outputs found
Studi di storia dell'arte in onore di Vittorio Viale.
No full textVittorio Viale, di G. C. Argan.--Il maestro degli apostoli a Prascorsano, di L. Mallé.--Un'aggiunta a una predella di Spanzotti nel Museo civico di Torino, di A. Bertini.--Un'opera tarda di Alvise Vivarini, di S. Bottari.--Un inedito d Gaudenzio, di G. Testori.--Una tavola del Sodoma, di E. Carli.--Fontainebleau in Italia, di E. Battisti.--Considerazioni su Tanzio da Varallo, di M. Calvesi.--Tre inediti, di N. Gabrielli.--La Madonna delle vigne presso Trino, di N. Carboneri.--Due vedute del Carlevarijs di R. Pallucchini.--Juvarra-Bernero a Stupinigi, di A. Griseri.--Due vedute del Carlevarijs, di R. Pallucchini.--Juvarra-Bernero a Stupinigi, di F. Russoli.--Gli acquisti d arazzi del Conte Verde e Nicolas Bataille, di M. Viale Ferrero.--Le opere d'arte di Torino e dintorni descritte da Francesco Paglia, di G. Panazza.--Is there an aesthetics of modern art?, di J.P. Hodin.--Omaggio a Sickert, di F. Arcangelii.--Tre opere in dono alla Galleria nazionale d'arte moderna, di P. Bucarelli.--Il futurismo e le arti applicate, pione e Renato Mazzacurati pittore, di V. Martinelli.--Motivo su Gianni Dova, d M. Valsecchi.--Technologia e arte, d M. Masciotta.--I "nouveaux réalistes" oggi, di G. Marchiori.--Pubblicazioni [di V. Viale] (p. 140-142).Architectuurfocu
Vittorio Viale et Mercedes Viale Ferrero, Aosta romana e medioevale , 1967
No full textNony Daniel. Vittorio Viale et Mercedes Viale Ferrero, Aosta romana e medioevale , 1967. In: Revue des Études Anciennes. Tome 71, 1969, n°3-4. p. 545
What is the Role of Fluoroquinolones in Intensive Care?
No full textFluoroquinolones are a class of antibiotics that are widely used in the treatment of a number of severe infections frequently observed in intensive care units (ICU). From a pharmacodynamic point of view, the optimal conditions for guaranteeing clinical recovery and preventing the occurrence of resistance to this class of antibiotics are represented by the ratios of C max/MIC >12.2 and AUC24h/MlC equal to 100-125 hours for Gram-negative bacteria, and about 30-40 hours for Gram-positive cocci. Taking this into consideration, the pharmacokinetics and pharmacodynamics shown in healthy volunteers suggest that with the use of standard doses of the various fluoroquinolones, an optimal AUCfree/MIC ratio for Gram-negative bacteria may be ensured with a minimum inhibitory concentration (MIC) <0.25-0.5 mg/L and for Gram-positive bacteria with an MIC <0.5-1 mg/L. The need to increase the dosage, or to combine them with other antibiotics is therefore recognized, when it is necessary to ensure adequate coverage of intermediately sensitive microorganisms (MIC 1-2 mg/L). In addition, patients recovered in the ICU often present some peculiar pathophysiological conditions that increase the distribution volume and/or the renal clearance of the drug. Thus it is likely that in this situation it would be reasonable to increase daily dosages, independent of the in vitro pattern of drug sensitivity (e.g. 500 mg b.i.d. for levofloxacin). Data from various clinical and pharmacological studies suggesting a potential role for fluoroquinolones both in monotherapy and combination therapy in the treatment of different clinically severe conditions are presented and discussed. This offers the dual opportunity to evaluate the role of quinolones as an alternative to aminoglycosides in combination with a beta-lactam and, at the same time, to consider their use in a periodic rotation program of anti-Gram-negative antibiotic therapy when there is a high risk of resistance selection, such as in the ICU. In conclusion, the role of fluoroquinolones in the treatment of multiple infectious diseases, such as bacteremia/sepsis, pneumonia and severe urinary tract infections in an environment such as the ICU is growing stronger, while there are convincing data indicating that these molecules might play a role in the treatment of meningitis in the near future
What does it mean: Appropriate therapy for methicillin-resistant Staphylococcus aureus? [17]
No full textThe antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?
No full textUntil recently, the in vitro susceptibility of microorganisms was considered the only fundamental aspect for antibiotic efficacy in treating pneumonia. However, the relevance of pharmacokinetic-pharmacodynamic relationships in optimizing drug exposure has been progressively highlighted. Antimicrobial agents were divided into concentration-dependent or time-dependent groups, with the most consistently relevant pharmacodynamic parameters for efficacy being either the ration of the plasma peak concentration to the minimum inhibitory concentration or the time the plasma concentration persists above the minimum inhibitory concentration of the etiological agent, respectively. For the adequate treatment of pneumonia, optimal pharmacodynamic exposure should be ensured also at the infection site. To investigate this, a methodologically correct approach may be to detect drug concentration levels in the epithelial lining fluid and in the alveolar macrophages for extracellular and intracellular pathogens, respectively. From this perspective, the pharmacokinetic factors-only in some instances-support the achievement of optimal exposure during the treatment of pneumonia with fixed standard dosing regimens of antimicrobials; conversely, in other instances, the pharmacokinetic factors suggest the need for an implemented dosage regimen or even the choice of a different drug. © 2006 by the Infectious Diseases Society of America. All rights reserved
Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of staphylococcus aureus bacteremia treated with vancomycin?
No full textShould the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?
No full textMethicillin-resistant (methicillin-resistant) Staphylococcus aureus causes unacceptably high mortality from ventilator-associated pneumonia, even when appropriate early therapy with vancomycin is administered at a dosage of 15 mg/kg every 12 hours. However, because of the poor penetration of vancomycin in epithelial lining fluid, it is unlikely that this dosing schedule always achieves optimal vancomycin exposure in the lung. Conversely, there is probably enough evidence to suggest that continuous infusion enhances vancomycin efficacy with the standard 30 mg/kg daily dosage, thus avoiding the need to use higher daily dosages that could increase the risk of nephrotoxicity. It is worth noting that in the case of fully susceptible pathogens with a minimum inhibitory concentration (MIC) of or =360, so that both pharmacodynamic efficacy targets may be optimized
Treating carbapenem-resistant Acinetobacter baumannii infections
No full textNot required for the type of articl
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?
No full text- …
